Baricitinib for the Prophylaxis of Graft-Versus-Host Disease After Peripheral Blood Hematopoietic Cell Transplantation
Status:
Recruiting
Trial end date:
2022-10-31
Target enrollment:
Participant gender:
Summary
In this trial, the investigators will begin to explore the possibility that, as in mice,
JAK1/2 inhibition with hematopoietic cell transplantation (HCT) may mitigate
graft-versus-host-disease (GVHD) while retaining engraftment and Graft-versus-Leukemia (GVL).
Both preclinical and clinical data suggest that inhibition of IFNy and IL-6, directly and
using downstream JAK Inhibitors, may be an effective strategy to decrease toxicities and
improve disease control for patients undergoing Allogeneic HSCT. Baricitinib, as a JAK1/2
inhibitor, has shown superiority to other JAK inhibitors in preclinical GVHD models. The
purpose of this phase I clinical trial is to determine the safety of baricitinib with HSCT
measured by the effect on engraftment and grade III-IV acute graft-versus-host-disease
(aGVHD).